Satsuma Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results
Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) reported Q3 2020 financial results, highlighting a net loss of $12.0 million ($0.69/share), up from $8.3 million ($2.26/share) in Q3 2019. The company holds $82.1 million in cash and equivalents, projected to fund operations through 2021. In the EMERGE Phase 3 trial for STS101, results showed numerical superiority for migraine treatment, achieving statistical significance beyond two hours post-administration. Satsuma is analyzing these outcomes and plans to update on development steps by early 2021.
- Cash reserves of $82.1 million will support operations through the end of 2021.
- STS101 demonstrated numerical superiority in migraine treatment at later time points in the EMERGE trial.
- No serious adverse events were reported for STS101 in the EMERGE trial.
- EMERGE trial did not achieve statistical significance on pre-specified co-primary endpoints at the two-hour mark.
- Net loss increased from $8.3 million in Q3 2019 to $12.0 million in Q3 2020.
- General and administrative expenses surged to $3.4 million, a significant rise from $1.0 million in Q3 2019.
- Analysis of results from EMERGE™ Phase 3 efficacy trial of STS101 ongoing; expect to communicate next steps by early 2021
- Cash, cash equivalents and marketable securities of $82.1 million as of September 30, 2020; based on current operating plans, expected to provide runway through end of 2021
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company focused on developing STS101 (a dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today reported financial results for the third quarter ended September 30, 2020 and provided a clinical development and corporate update.
“As reported in early September, the EMERGE Phase 3 efficacy trial of STS101 as an acute treatment for migraine did not achieve statistical significance on the pre-specified co-primary endpoints (freedom from pain and most bothersome symptom) at the two-hour post-administration time point,” commented John Kollins, Satsuma’s President and Chief Executive Officer. “However, we remain encouraged that STS101 demonstrated numerical superiority on these endpoints at two hours following administration, with statistical significance achieved at three hours and all later time points.”
Mr. Kollins continued, “Given the STS101 efficacy signal observed in the EMERGE trial, as well as the favorable STS101 safety and tolerability profile observed to date, we are methodically analyzing EMERGE trial data in order to understand the reasons for the trial outcome and to inform our decisions regarding potential plans to advance development of STS101. We anticipate providing an update on our business plans by early 2021 after completing our analyses.”
Recent Highlights
STS101
Analysis of results from EMERGE™ Phase 3 efficacy trial ongoing
In early September, Satsuma reported topline data from the EMERGE Phase 3 efficacy trial of STS101. Although topline data showed numerical differences in favor of STS101 3.9 mg and 5.2 mg versus placebo on the pre-specified co-primary endpoints of freedom from pain and freedom from most bothersome symptom (from among photophobia, phonophobia and nausea) at two hours post-administration, these differences did not achieve statistical significance for either dose strength. Both dose strengths of STS101 did, however, demonstrate significant effects on both freedom from pain and most bothersome symptom by three hours post-dose and all later time points. Consistent with the results to date observed in other STS101 clinical trials, both STS101 dose strengths were well-tolerated in the EMERGE trial, with low adverse event rates and no serious adverse events reported.
The EMERGE study was designed in accordance with FDA recommendations outlined in the FDA Guidance Document, Migraine: Developing Drugs for Acute Treatment, February 2018.
ASCEND™ Phase 3 open-label long-term safety trial
In August, Satsuma initiated patient enrollment in the ASCEND open-label safety and tolerability trial in which patients will treat their migraines on an as-needed basis with STS101 for up to 12 months. The trial is expected to enroll up to 300 migraine patients, with at least 150 treating a minimum of two attacks per month with STS101 over a six-month period and at least 50 over a 12-month period.
Expansion of Intellectual Property Portfolio
Satsuma continues to expand its intellectual property portfolio, with the U.S. Patent and Trademark Office recently issuing two U.S. patents relating to STS101, one owned and one exclusively licensed by Satsuma, with expiration dates in 2039 and 2037, respectively, not including any potential adjustments or extensions of term. The issuance of these patents brings the total number of issued U.S. patents exclusively licensed or owned by Satsuma to ten, and in total, Satsuma currently has exclusive license rights under more than sixty U.S. and foreign patents and pending applications. The Company believes that the breadth of its intellectual property portfolio reflects the highly innovative and differentiated nature of the proprietary dry-powder nasal delivery and formulation technologies incorporated in STS101.
Financial Results for Third Quarter 2020
Net loss for the third quarter 2020 was
Research and development expenses were
General and administrative expenses were
About Satsuma Pharmaceuticals and STS101
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product candidate for the acute treatment of migraine. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. DHE products have long been recommended as a first-line therapeutic option for the acute treatment of migraine and have significant advantages over other therapeutics for many patients. However, broad use has been limited by invasive and burdensome administration and/or sub-optimal clinical performance of available injectable and liquid nasal spray products. STS101 is specifically designed to deliver the clinical advantages of DHE while overcoming these shortcomings.
Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit www.satsumarx.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements concerning the business, operations and financial performance and condition of Satsuma Pharmaceuticals, Inc. (the “Company”), as well as the Company’s plans, objectives and expectations for its business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about the potential continued development of STS101; the Company’s expectations regarding the completion of its analysis of the EMERGE trial data and announcement of its updated business plans by early 2021; Company’s expectations regarding the potential safety and efficacy of STS101; the Company’s clinical and regulatory development plans; the Company’s expectations with regard to the ASCEND trial; the Company’s expected cash needs and sufficiency of cash on hand to fund its operations until the end of 2021. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, to be filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of STS101; the risk that the COVID-19 worldwide pandemic may negatively impact the Company’s business, operations, clinical trials or ability to raise capital; the unpredictability of the regulatory process; regulatory developments in the United States and foreign countries; the costs of clinical trials may exceed expectations; and the Company’s ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
This press release discusses STS101, a product candidate that is in clinical development, and which has not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of STS101 for the therapeutic use for which STS101 is being studied.
INVESTOR AND CORPORATE CONTACTS:
Corey Davis, PhD
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
Tom O’Neil, Chief Financial Officer
Satsuma Pharmaceuticals, Inc.
tom@satsumarx.com
| SATSUMA PHARMACEUTICALS, INC. Condensed Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) (unaudited) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | $ | 8,750 | $ | 7,441 | $ | 27,227 | $ | 15,046 | ||||||||
| General and administrative | 3,420 | 1,029 | 8,614 | 2,560 | ||||||||||||
| Total operating expenses | $ | 12,170 | $ | 8,470 | $ | 35,841 | $ | 17,606 | ||||||||
| Loss from operations | (12,170 | ) | (8,470 | ) | (35,841 | ) | (17,606 | ) | ||||||||
| Interest income | 209 | 331 | 1,036 | 602 | ||||||||||||
| Interest expense | (82 | ) | (121 | ) | (280 | ) | (365 | ) | ||||||||
| Other income, net | — | — | — | 3 | ||||||||||||
| Net loss | $ | (12,043 | ) | $ | (8,260 | ) | $ | (35,085 | ) | $ | (17,366 | ) | ||||
| Unrealized gain (loss) on marketable securities | (150 | ) | 12 | 68 | 12 | |||||||||||
| Comprehensive loss | $ | (12,193 | ) | $ | (8,248 | ) | $ | (35,017 | ) | $ | (17,354 | ) | ||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.69 | ) | $ | (2.26 | ) | $ | (2.02 |
{
"@context": "https://schema.org",
"@type": "FAQPage",
"name": "Satsuma Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results FAQs",
"mainEntity": [
{
"@type": "Question",
"name": "What were the financial results for Satsuma Pharmaceuticals in Q3 2020?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Satsuma reported a net loss of $12.0 million, or $0.69 per share, compared to $8.3 million, or $2.26 per share in Q3 2019."
}
},
{
"@type": "Question",
"name": "What is the status of the STS101 drug trial?",
"acceptedAnswer": {
"@type": "Answer",
"text": "The EMERGE Phase 3 trial showed STS101's numerical superiority for treating migraines, with statistical significance at three hours post-dose."
}
},
{
"@type": "Question",
"name": "What is the cash position of Satsuma Pharmaceuticals as of September 30, 2020?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Satsuma had $82.1 million in cash, cash equivalents, and marketable securities, expected to support operations through the end of 2021."
}
},
{
"@type": "Question",
"name": "When can investors expect updates on Satsuma's clinical development plans?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Satsuma plans to provide an update on their business plans and the analyses from the EMERGE trial by early 2021."
}
}
]
}
FAQ
What were the financial results for Satsuma Pharmaceuticals in Q3 2020?
Satsuma reported a net loss of $12.0 million, or $0.69 per share, compared to $8.3 million, or $2.26 per share in Q3 2019.
What is the status of the STS101 drug trial?
The EMERGE Phase 3 trial showed STS101's numerical superiority for treating migraines, with statistical significance at three hours post-dose.
What is the cash position of Satsuma Pharmaceuticals as of September 30, 2020?
Satsuma had $82.1 million in cash, cash equivalents, and marketable securities, expected to support operations through the end of 2021.
When can investors expect updates on Satsuma's clinical development plans?
Satsuma plans to provide an update on their business plans and the analyses from the EMERGE trial by early 2021.
STSA
NASDAQ:STSASTSA RankingsSTSA Latest NewsSTSA Stock Data | |||||||